Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817320 | 0.81 | KARS1 (0.35) | ZAP70KARS1 | |
| SCHEMBL24728224 | 0.78 | NR3C1 (0.34) | ZAP70KARS1 | |
| SCHEMBL24728146 | 0.77 | CARM1 (0.32) | CARM1 | |
| SCHEMBL23685895 | 0.73 | AHR (0.42) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14329071 | 0.70 | GABRA1 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14330927 | 0.70 | TRPA1 (0.34) | SLC6A2 | |
| SCHEMBL23475222 | 0.69 | CYP1A2 (0.36) | — | |
| SCHEMBL20314900 | 0.68 | USP2 (0.41) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4805952 | 0.68 | GABRA1 (0.44) | — | |
| SCHEMBL17661909 | 0.68 | GABRA1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388968-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388968-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | SPTBN1, CTTN, HBG1 | ZAP70 657/4885CARM1 1493/4885P2RX3 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.